Context Therapeutics
PHILADELPHIA, PA · Founded 2021 · CIK 0001842952 · Biotech · Public
Therapeutics for female cancers
contexttherapeutics.com →- Grants
- $450K
- 2 awards
- Sector median: 1
- Raised
- $100M
- 1 Form D · May 2024
- 29 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 10
- 0 granted · 10 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201620172018201920202021202220232024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · A Potent Small Molecule Sigma1 Modulator Degrades Androgen Receptor In Castration Resistant Prostate Cancer | $225,222 | |
| Federal grant | Department of Health and Human Services · Phase I · A Potent Small Molecule Sigma1 Modulator Degrades Androgen Receptor In Castration Resistant Prostate Cancer | $225,222 | |
| Private capital raised | Form D · SEC | $99,992,767 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2168 | Ocugen | — | $126M |
| 2169 | VISIONARY PHARMACEUTICALS, INC. | — | — |
| 2170 | Excision BioTherapeutics Inc. | — | $71M |
| 2171 | Context Therapeutics | — | $100M |
| 2172 | QT Holdings Corp. | — | $3.8M |
| 2173 | LOKI THERAPEUTICS, INC | — | — |
| 2174 | Aruvant Sciences | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Richard BermanDirector
- Jennifer Evans StaceyDirector
- Philip KantoffDirector
- Martin LehrDirector · Executive Officer
- Alex LevitExecutive Officer
- Jennifer Minai-AzaryExecutive Officer
- Linda WestDirector
Patents
- Bispecific Antibodies And Methods Of Using The Sameapplication
- Compositions Comprising Bispecific Antibodies That Bind To Claudin 6 And CD3, And Uses Thereofapplication
- Methods Of Identifying And Treating Tumors With SIGMA1 Inhibitorsapplication
- Methods Of Identifying And Treating Tumors With SIGMA1 Inhibitorsapplication
- Methods Of Identifying And Treating Tumors With SIGMA1 Inhibitorsapplication
- Compositions Comprising Bispecific Antibodies That Bind To Claudin 6 And CD3, And Uses Thereofapplication
- Methods Of Identifying And Treating Tumors With SIGMA1 Inhibitorsapplication
- Bispecific Antibodies And Methods Of Using The Sameapplication
- Compositions Comprising Bispecific Antibodies That Bind To Claudin 6 And CD3, And Uses Thereofapplication
- Bispecific Antibodies And Methods Of Using The Sameapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.